Insider Buying: Tilray Inc (NASDAQ:TLRY) CFO Purchases 26,000 Shares of Stock

Tilray Inc (NASDAQ:TLRY) CFO Carl A. Merton purchased 26,000 shares of Tilray stock in a transaction on Friday, November 15th. The shares were acquired at an average price of $1.36 per share, with a total value of $35,360.00. Following the transaction, the chief financial officer now directly owns 26,000 shares in the company, valued at $35,360. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tilray Stock Down 1.9 %

Shares of NASDAQ:TLRY traded down $0.03 during trading on Monday, reaching $1.33. 18,903,356 shares of the company traded hands, compared to its average volume of 25,484,760. Tilray Inc has a 1-year low of $1.30 and a 1-year high of $2.97. The company has a quick ratio of 1.57, a current ratio of 2.47 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.20 billion, a P/E ratio of -4.87 and a beta of 2.14. The firm has a fifty day simple moving average of $1.65 and a 200 day simple moving average of $1.76.

Tilray (NASDAQ:TLRY) last posted its earnings results on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The company had revenue of $200.00 million during the quarter, compared to the consensus estimate of $218.70 million. During the same period in the previous year, the firm posted ($0.10) earnings per share. The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. Analysts anticipate that Tilray Inc will post -0.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Roth Mkm decreased their target price on Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a research note on Friday, October 11th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Tidal Investments LLC increased its stake in shares of Tilray by 36,687.0% in the first quarter. Tidal Investments LLC now owns 10,677,428 shares of the company’s stock worth $26,373,000 after purchasing an additional 10,648,403 shares during the period. BNP Paribas Financial Markets increased its position in Tilray by 1,314.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company’s stock worth $3,202,000 after buying an additional 1,690,827 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Tilray during the third quarter worth approximately $1,348,000. Bank of Montreal Can boosted its position in shares of Tilray by 19.6% in the second quarter. Bank of Montreal Can now owns 2,169,100 shares of the company’s stock valued at $3,622,000 after acquiring an additional 355,778 shares during the period. Finally, XTX Topco Ltd increased its position in Tilray by 1,079.7% during the third quarter. XTX Topco Ltd now owns 281,504 shares of the company’s stock worth $495,000 after acquiring an additional 257,641 shares during the period. Institutional investors and hedge funds own 9.35% of the company’s stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.